Document is current
Any future updates will be listed below
-
Authors
Bhaskaran, Vivek https://orcid.org/0000-0002-5100-4787
Nowicki, Michal O.
Idriss, Mahmoud
Jimenez, Miguel A. https://orcid.org/0000-0002-0249-1208
Lugli, Gianmarco https://orcid.org/0000-0001-6626-3258
Hayes, Josie L.
Mahmoud, Ahmad Bakur
Zane, Rachel E.
Passaro, Carmela
Ligon, Keith L.
Haas-Kogan, Daphne
Bronisz, Agnieszka
Godlewski, Jakub
Lawler, Sean E.
Chiocca, E. Antonio
Peruzzi, Pierpaolo https://orcid.org/0000-0001-5034-2963
- License Information
-
More Information
Article History
Received: 12 July 2018
Accepted: 7 January 2019
First Online: 25 January 2019
Competing interests
: E.A.C. is currently an advisor to Advantagene Inc., Alcyone Biosciences, Insightec, Inc., Sigilon Therepeutics and DNAtrix Inc. and has equity interest in DNAtrix; he has also advised Oncorus, Merck, Tocagen, Ziopharm, Stemgen, NanoTx., Ziopharm Oncology, Cerebral Therapeutics, Genenta, Janssen, Karcinolysis, and Shanghai Biotech. The other authors declare no competing interests.
